Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Operating Expenses (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Operating Expenses for 4 consecutive years, with $21.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses rose 22.19% to $21.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $78.1 million, a 24.39% increase, with the full-year FY2024 number at $66.9 million, up 23.35% from a year prior.
  • Operating Expenses was $21.2 million for Q3 2025 at Orchestra BioMed Holdings, up from $20.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $21.2 million in Q3 2025 to a low of $6.0 million in Q1 2022.
  • A 4-year average of $14.6 million and a median of $14.9 million in 2023 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: surged 112.03% in 2023, then rose 14.32% in 2025.
  • Orchestra BioMed Holdings' Operating Expenses stood at $10.9 million in 2022, then rose by 16.58% to $12.7 million in 2023, then soared by 32.86% to $16.9 million in 2024, then increased by 25.07% to $21.2 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Operating Expenses are $21.2 million (Q3 2025), $20.2 million (Q2 2025), and $19.8 million (Q1 2025).